Sulforaphane impaired immune checkpoint blockade therapy through activating ΔNP63α/PD‐L1 axis in gastric cancer-Reference-Cited by-同舟云学术

Sulforaphane impaired immune checkpoint blockade therapy through activating ΔNP63α/PD‐L1 axis in gastric cancer

Published:2024-05-23 Issue:8 Volume:63 Page:1611-1620
ISSN:0899-1987
Container-title:Molecular Carcinogenesis
language:en
Short-container-title:Molecular Carcinogenesis

Author:

Zhang Qi¹,Yang Chenying²,Ma Zhijian³,Ye Liangwen⁴,Wu Yunfeng³,Zhong Caiyun⁵^ORCID,Shi Ye⁶,Zhu Mingming³

Affiliation:

1. Department of Public Health, School of Medicine Nanjing University of Chinese Medicine Nanjing China

2. Yinzhou Center for Disease Control and Prevention Ningbo China

3. Department of Nutrition, School of Acupuncture and Tuina Nanjing University of Chinese Medicine Nanjing China

4. The First Clinical Medical College Nanjing University of Chinese Medicine Nanjing China

5. Department of Nutrition and Food Safety, Center for Global Health, School of Public Health Nanjing Medical University Nanjing China

6. Department of Thoracic Surgery, Nanjing Chest Hospital, Affiliated Nanjing Brain Hospital Nanjing Medical University Nanjing China

Abstract

AbstractSulforaphane (SFN) exerts anticancer effect on various cancers including gastric cancer. However, the regulatory effect of SFN on programmed death‐ligand 1 (PD‐L1) and checkpoint blockade therapy in gastric cancer have not been elucidated. Here we demonstrated that SFN suppressed gastric cancer cell growth both in vitro and in vivo study. SFN upregulated PD‐L1 expression through activating ΔNP63α in gastric cancer cells. Further, we found that SFN impaired the anticancer effect of anti‐PD‐L1 monoclonal antibody (α‐PD‐L1 mab) on gastric cancer cells. These results uncover a novel PD‐L1 regulatory mechanism and the double‐edged role of SFN in gastric cancer intervention.

Funder

National Natural Science Foundation of China

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mc.23749

Reference33 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Gastric cancer: a comprehensive review of current and future treatment strategies

3. Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)

4. Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients

5. Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial